Paliperidone to Treat Psychotic Disorders

Abstract

Purpose of Review: This is a comprehensive review of the literature regarding the use of paliperidone in the treatment of schizophrenia and schizoaffective disorder. It covers the background and presentation of schizophrenia and schizoaffective disorder, as well as the mechanism of action and drug information for paliperidone. It covers the existing evidence of the use of paliperidone for the treatment of schizophrenia and schizoaffective disorder. Recent Findings: Schizophrenia and schizoaffective disorder lead to significant cognitive impairment. It is thought that dopamine dysregulation is the culprit for the positive symptoms of schizophrenia and schizoaffective disorder. Similar to other second-generation antipsychotics, paliperidone has affinity for dopamine D2 and serotonin 5-HT2A receptors. Paliperidone was granted approval in the United States in 2006 to be used in the treatment of schizophrenia and in 2009 for schizoaffective disorder. Summary: Schizophrenia and schizoaffective disorder have a large impact on cognitive impairment, positive symptoms and negative symptoms. Patients with either of these mental illnesses suffer from impairments in everyday life. Paliperidone has been shown to reduce symptoms of schizophrenia and schizoaffective disorder.

Treatment of Patients With Schizophrenia and Comorbid Chronic Hepatitis With Paliperidone: A Systematic Review

“…Due to its high tolerance, individuals tolerated paliperidone palmitate better than they did other antipsychotic medications [ 4 ]. Due to paliperidone's equal efficacy to its parent component risperidone, greater safety, and higher patient satisfaction, it may be more advantageous [ 13 ]. Also, receiving treatment with paliperidone considerably lowers both the frequency and length of hospital stays.…”

“…In the same study, it was also stated that patients with stable active hepatic disease who have schizophrenia or schizoaffective disorder tolerate paliperidone effectively [ 9 ]. According to another study by Minwalla et al, it can be difficult to manage senior schizophrenia patients since they often have reduced kidney and liver functions; in such cases, paliperidone has proved to be superior to other antipsychotics as it is less influenced by changes in metabolism [ 13 ].…”

Inhibition of voltage‐dependent K+ currents of rabbit coronary arterial smooth muscle cells by the atypical antipsychotic paliperidone

“…As paliperidone does not compromise hepatic function, it is recommended for patients with hepatic and renal impairments (Boom et al, 2009; Dolder, Nelson, & Deyo, 2008; Wesołowska, Jastrzębska‐Więsek, Cios, & Partyka, 2020). However, as is true of all atypical antipsychotics, its side effects include orthostatic hypotension, weight gain, hyperglycemia, cognitive impairment, and seizures (Minwalla et al, 2021). Side effects on ion channels have also been reported.…”

Development and Characterization of Paliperidone Loaded Nanostructured Lipid Carrier

“…Even if the mechanism of action of paliperidone is not completely well-known, principally it acts as an antagonist of dopamine D (2) and serotonin 5HT (2A) receptors. 13 It is marketed as a racemic mixture. 14 under the brand name 'Invega' by Janssen pharmaceuticals.…”